LTRN
Lantern Pharma Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.64
−4.05%Oct 7, 2026, 12:31 UTC
The lead Taiwan trial site received local Institutional Review Board approval to open Part 2 of Lantern Pharma Inc.'s Phase 2 HARMONIC trial of LP-300.
Source:Oct 1, 2026, 20:09 UTC
Lantern Pharma Inc. received a NASDAQ notice dated September 25, 2026 that it no longer complies with the $35 million market value of listed securities requirement under Rule 5550(b)(2), with a compliance deadline of March 24, 2027.
Sep 30, 2026, 20:15 UTC
Lantern Pharma Inc. signed a registered direct offering of common stock and pre-funded warrants to raise approximately $4 million, with a concurrent private placement of purchase warrants.
Source:Sep 22, 2026, 20:45 UTC
TikTok US joined the child safety initiative Lantern, whose members including Meta and X shared more than 2 million signals of potentially violating behavior from 2023 through 2025.
Source:Sep 22, 2026, 14:00 UTC
TikTok USDS Joint Venture joined Lantern, a cross-platform child safety initiative, and committed $2 million to the National Center for Missing and Exploited Children's CyberTipline modernization.
Source:Sep 22, 2026, 11:45 UTC
The United States Patent and Trademark Office issued a Notice of Allowance for Lantern Pharma's U.S. Patent Application No. 18/500,032 covering the use of its drug candidate LP-284 to treat mantle cell lymphoma and other aggressive B-cell lymphomas.
Source:Sep 17, 2026, 12:20 UTC
Lantern Pharma announced it will host a live webinar on September 23, 2026 to present the business model, development roadmap, and value proposition of Open-Medicine AI, its wholly owned subsidiary building a multi-agentic AI platform for end-to-end therapeutic development.
Source:Aug 14, 2026, 11:30 UTC
Lantern Pharma reported its financial results for the second quarter of 2026 and provided a business update.
Source:Aug 3, 2026, 11:30 UTC
Lantern Pharma established Open-Medicine AI as a separate company to commercialize and expand its multi-agent AI co-scientist platform.
Source:Jul 23, 2026, 12:01 UTC
Lantern Pharma received a Notice of Allowance from the USPTO for a patent covering biomarker-guided treatment with LP-184 in multiple solid tumor cancers.
Source:Jul 8, 2026, 11:30 UTC
Lantern Pharma launched ZetaOmics, an autonomous computational biologist module of its AI co-scientist platform, for cancer bioinformatics analysis.
Source: